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Objective. To determine the first signs and symptoms, and the clinical, biological and radiological characteristics of patients with early SpA.
Methods. A total of 150 SpA patients were selected from 2367 listed in REGISPONSER (Registro Espan ˜ol de Espondiloartritis de la
Sociedad Espan ˜ola de Reumatologı ´a). The inclusion criterion was a disease course of 42 yrs from the onset of symptoms or the appearance
of the first sign of disease.
Results. Forty-six patients had AS, 51 psoriatic SpA (Ps-SpA), 43 uSpA, 5 ReA, 4 IBD arthropathy and 1 JCA. The mean age at onset of
symptoms and at diagnosis was higher in Ps-SpA group (48.1 13.6 and 48.5 13.6 yrs) than in AS group (38.1 12.8 and 38.9 12.7 yrs)
and uSpA group (36.3 11.5 and 36.9 11.4 yrs). The most frequent signs or symptoms were back pain: 72% AS group and 56% uSpA
group. Lower limb arthritis was the first symptom in 57% Ps-SpA patients, 35% uSpA patients and 20% AS patients; upper limb arthritis was
the first symptom in 53% Ps-SpA group and <16% of the remainder. Compared with longer duration disease, at onset, AS patients report
upper limb arthritis more frequently and uSpA patients report more of enthesitis. Early radiological sacroiliitis was observed in all AS patients,
of whom 54% had Grade II, 39% had Grade III and 7% had Grade IV.
Conclusions. In our population, the first manifestations of SpA were low back pain and SI syndrome in AS and uSpA patients and peripheral
arthritis in the Ps-SpA group. We can find early SI joint affectation in AS patients.
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Introduction
The inflammatory rheumatic diseases affecting the spine are
included in the heterogeneous group of SpA. The group is formed
by AS (the most common), psoriatic SpA (Ps-SpA), IBD arthro-
pathy (IBDA), ReA, uSpA and JCA. They all share clinical
manifestations (the most important being inflammatory back
pain), radiological manifestations (sacroiliitis) and genetic traits
(such as a strong association with HLA-B27) [1]. The global
prevalence of these entities ranges from 0.23% to 1.8% [2].
Despite the remarkable increase in our knowledge of the
epidemiological, clinical and therapeutic aspects of these diseases,
we know very little about their onset pattern. In fact, the delay
in diagnosis (6.5 8.4 yrs in Spain) [3] in patients suffering
from this condition means that it is difficult to determine how they
progress between onset and the first clinical manifestations.
Patient registries can provide information on recently diagnosed
patients and enable us to avoid the memory bias that frequently
burdens population studies. In April 2004, the Spanish Spondy-
loarthropathy Study Group of the Spanish Society of Rheuma-
tology (GRESSER) began the National Registry of
Spondyloarthritis [Registro Espan ˜ ol de Espondiloartritis de la
Sociedad Espan ˜ ola de Reumatologı´a (REGISPONSER)] [3].
Today, it has more than 2000 patients (150 of whom have <2
yrs of disease duration). Data are available on patient character-
istics, clinical aspects, radiological presentation and therapeutic
response. This registry has been the basis for describing the
clinical, socio-demographic, analytical, radiological and metrolo-
gical features of patients with SpA in Spain. We consider that the
information provided by our cohort could add to our knowledge
of the early stages of SpA.
The REGISPONSER-Early cohort was created and followed to
the present day in an attempt to fill some of the gaps in our
knowledge of this condition.
In this article, we will try to clarify about the beginning of these
diseases and how the memory bias influences the knowledge of the
onset.
Patients and methods
Patients
We selected 150 SpA patients from the 2367 listed in
REGISPONSER (National Registry of Spondyloarthropathy:
http://biobadaser.ser.es/cgi-bin/regisponser/index.html). The inclu-
sion criteria for the register were: fulfilment of the classification
criteria from the European Spondyloarthropathy Study Group
(ESSG) [4], blood tests available within 15 days of the inclusion visit
and a complete radiographic study within the previous year, and
agreement to complete all self-administered questionnaires. This
project was approved by the Committee of Ethical and Sanitary
Investigation of the ‘Reina Sofı´a’ University Hospital according
to the fundamental principles established in the Declaration of
Helsinki, in the council of Europe Convention for Human Rights
and every patient signed an informed patient consent at inclusion
in REGISPONSER.
For this study, we selected patients with a disease course of
42 yrs from the onset of symptoms or the appearance of the first
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symptoms (inflammatory back pain as defined by Calin criteria
[5], SI syndrome, dactylitis, enthesitis according to MASES—
Maastricht Ankylosing Spondylitis Enthesitis Score assessment
criteria [6], cervical pain, lower limb arthritis and upper limb
arthritis) and the extra-articular-related pathology psoriasis.
Forty-six (30.7%) of the 150 patients fulfilled the modified
New York criteria for AS, 51 (34%) had Ps-SpA, 43 (28.7%) had
uSpA, 5 (3.3%) had ReA, 4 (2.7%) had IBDA and 1 (0.7%) had
JCA.
In order to streamline the statistical analysis, only three sub-
groups were formed, namely, those with the largest number of
patients (AS, Ps-SpA and uSpA). These 140 SpA patients
constitute the REGISPONSER-Early cohort and whose char-
acteristics are provided in this article.
We also selected 1383 SpA patients from REGISPONSER
who had >10 yrs of evolution from the onset of signs/symptoms
attributable to the disease and with the three main diagnoses
named before. Of the total 1383 patients, 1074 (77.7%) patients
had AS, 187 (13.5%) had Ps-SpA and 122 (8.8%) had uSpA. This
subgroup is called as ‘REGISPONSER-Late’ in this article.
Data collection
Data collection was given in detail in one of our previous
paper [3].
Statistical analysis
A descriptive analysis was made of the epidemiological, clinical,
radiographic and analytical variables according to the different
diagnoses.
Comparisons of continuous variables between groups were
made by analysis of variance, and the Tukey or Games–Howell
tests were used for post hoc testing. Kruskal–Wallis test for ordinal
variables and Mann–Whitney for post hoc test were used. Cate-
gorical variables were compared using the chi-square test. Differ-
ences with a P-value of <0.05 were considered to be statistically
significant.
Results
The clinical characteristics of this cohort are presented in Table 1.
We found a higher percentage of women in the uSpA group than
in the AS and Ps-SpA groups (without statistical difference) and
we observed a greater presence of HLA-B27 in the AS and uSpA
groups (P<0.001). The mean age at onset of symptoms and age at
diagnosis were higher in the Ps-SpA than in the AS and uSpA
groups (P<0.001). Total REGISPOSER-Early sub-cohort media
of age at onset compared with REGISPONSER-Late media was
also higher (41.2 13.6 vs 26.7 10.5, P<0.001). Ps-SpA first’s
signs/symptoms were mostly upper and lower limb arthritis (53
and 57%, respectively) and 82% presented psoriasis at the onset
of SpA. The diagnosis delay in this series of patients was <1yrin
all groups.
First clinical manifestations
The first clinical manifestations attributable to the disease by each
group and compared with REGISPONSER-Late cohort are
presented in Table 2. The initial most common symptom was
inflammatory back pain, both globally and by group; SI syn-
drome, defined as alternating pain that affects the buttocks, was
the initial symptom in 46% of the AS patients and in 35% of the
uSpA patients. Dactylitis was not observed at onset in patients
with AS, was present in 10% of all Ps-SpA cases and in 7% of
uSpA cases. Enthesitis was observed more frequently at the onset
of uSpA (28%) than in the other groups (<13%; P¼0.046).
TABLE 1. Characteristics of patients, by specific diagnosis
AS (n¼46) Ps-SpA (n¼51) uSpA (n¼43) P Total (n¼140)
Men, n (%) 33 (72) 31 (61) 25 (58) 0.36 89 (64)
Age, yrs 39.5 12.7 49.3 13.6
  37.8 11.4
  <0.001 42.6 13.6
Age at diagnosis, yrs 38.9 12.7 48.5 13.6
  36.9 11.4
   <0.001 41.8 13.6
Age at onset
a, yrs 38.1 12.8 48.1 13.6
  36.3 11.5
   <0.001 41.2 13.7
Time of evolution
a, yrs 1.5 0.6 1.2 0.7 1.5 0.7 0.20 1.4 0.7
HLA-B27 positive, n (%) 33/40 (82) 8/35 (23)
  25/38 (66)
   <0.001 66/113 (58)
Disease duration
b, yrs 0.7 0.7 0.9 0.7 0.9 0.7 0.30 0.8 0.7
Diagnosis delay, yrs 0.8 0.6 0.4 0.6
  0.6 0.7 0.005 0.6 0.6
Results are expressed as a mean  S.D. unless otherwise specified. Significance was obtained using the chi-square test for qualitative variables and analysis of variance for quantitative variables
(Tukey as post hoc test).
aFrom the first signs/symptoms attributable to the disease.
bFrom the date of the diagnosis.
 Significant differences (P<0.05) vs AS.
  Significant differences (P<0.05) vs
Ps-SpA.
TABLE 2. First signs/symptoms attributable to the disease
AS Ps-SpA uSpA P
 2yrs (n¼46) >10yrs (n¼1074)  2yrs (n¼51) >10yrs (n¼187)  2yrs (n¼43) >10yrs (n¼122)  2yrs >10yrs
Low back pain 33 (72) vs 769 (72)
P¼0.98
13 (26)
  vs 31 (17)
 
P¼0.15
24 (56)
   vs 62 (51)
 ,  
P¼0.57
<0.001 <0.001
SI syndrome 21 (46) vs 443 (41)
P¼0.55
6 (12)
  vs 17 (9)
 
P¼0.59
15 (35)
   vs 35 (29)
 ,  
P¼0.45
0.001 <0.001
Neck pain 3 (6) vs 121 (11)
P¼0.31
1( 2 )vs 14 (7)
P¼0.20
2( 5 )vs 6( 5 )
 
P¼1
0.54 0.038
Dactylitis 0 vs 12 (1)
P¼1
5 (10) vs 17 (9)
 
P¼0.79
3( 7 )vs 3( 3 )
  
P¼0.18
0.10 <0.001
Arthritis, lower limbs 9 (20) vs 176 (16)
P¼0.57
29 (57)
  vs 131 (70)
 
P¼0.08
15 (35)
   vs 40 (33)
 ,  
P¼0.80
<0.001 <0.001
Arthritis, upper limbs 7 (15) vs 37 (3)
P<0.001
27 (53)
  vs 106 (57)
 
P¼0.63
7 (16)
   vs 13 (11)
 ,  
P¼0.33
<0.001 <0.001
Enthesitis 6 (13) vs 75 (7)
P¼0.14
5 (10) vs 15 (8)
P¼0.78
12 (28)
   vs 18 (15)
 
P¼0.05
0.046 0.010
Dates are expressed as n (%). Significance obtained by the chi-square test for contingency tables.
 Significant differences (P<0.05) vs AS within each group of time of evolution.
  Significant
differences (P<0.05) vs Ps-SpA within each group of time of evolution. Comparison of REGISPONSER-Early vs ‘REGISPONSER-Late’.
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was more frequent in the lower limbs (38%) than in the upper
limbs (29%). The rating by group reveals that the frequency was
significantly higher in Ps-SpA patients than in uSpA and AS
patients (P<0.001).
Comparing these first manifestations with REGISPONSER-
Late we can see that patients with early AS report upper limb
arthritis more frequently (15% vs 3%, P<0.001) and those
with early uSpA present with more of enthesitis (28% vs 15%,
P¼0.05); other comparisons did not reach statistically significant
differences.
Clinical features at inclusion
Clinical manifestations at inclusion in the registry, metrological
data and radiological characteristics are presented in Table 3.
Enthesitis affected 26% of the uSpA and 24% of the AS patients
with a lower frequency in the other SpA. Uveitis was present in
9% of the AS patients and 7% of the uSpA patients. Peripheral
joint was more frequent in the Ps-SpA group (51%) than in the
other groups (21% uSpA and 20% AS; P<0.001).
Chest expansion was lower in Ps-SpA patients than in AS and
uSpA patients (P¼0.06). Lumbar flexibility, as measured by the
Schober’s test, was preserved in all groups, with the highest values
in the uSpA group (P¼0.016). The occiput-to-wall distance was
higher in the AS group than in the Ps-SpA and uSpA groups
(P¼0.16). The finger-to-floor distance was greater in the AS
group (slightly greater than that of the Ps-SpA group and some-
what greater than that of the uSpA group; P¼0.06). Cervical
rotation was between 208 and 708 in 22% of the AS patients, 18%
of the Ps-SpA patients and 7% of the uSpA patients (P¼0.13).
No patients had a rotation of <208.
Disease activity
The analysis of disease activity parameters at inclusion is
presented in Table 4 (no statistical difference was found in this
analysis). We found that nocturnal pain measured by the visual
analogue scale (VAS) was greater in patients with AS than in
those with uSpA and Ps-SpA; activity levels valued by the patient
with the VAS were slightly higher in the Ps-SpA group. The phy-
sician’s global assessment measured by VAS was almost similar in
the three main groups, and somewhat lower in the group with less
frequent SpA. The ESR and levels of CRP were slightly higher in
the Ps-SpA group than in the AS and uSpA groups. As for the
functional status of physical and mental components measured
according to the SF-12 questionnaire [7], the averages of the three
main groups showed no major differences; a lower score (which
means a better functional status) was observed in the less frequent
SpA group.
Radiographic scores
As expected, sacroiliitis was found in all patients with AS, of
whom 54% had Grade II, 39% had Grade III and 7% had Grade
IV sacroiliitis. In Ps-SpA group, 74% of the patients had no
radiological sacroiliitis, 8% had Grade I, 10% Grade II and 8%
had Grade III sacroiliitis; and no Grade IV was found. In uSpA
group, 83% had Grade 0–I sacroiliitis (34 and 49%, respectively),
15% had Grade II and 2% had Grade III sacroiliitis (corre-
sponding to one patient who did not fulfil the New York clinical
criteria for AS). Low radiographic scores by Bath Ankylosing
Spondylitis Radiological Index (BASRI) were found in general
(Table 5, Fig. 1), but AS had always higher punctuation (P<0.05)
except on assessment of the hips vs PS-SpA (P>0.05) except on
assessment of the hip vs ps-SpA (P<0.05).
Comparing the AS and uSpA groups
As the tables show, there are differences in demographic and
clinical characteristics, metrological data and activity indicators
between these two groups of patients, although these were not
statistically significant in most cases.
The metrological data in Table 3 show that, in AS patients, the
mean result of the Schober’s test is lower than that of uSpA
patients, with a statistically significant difference (P¼0.014). The
AS group has an increased finger-to-floor distance (P¼0.02),
which is indicative of lower lumbar spine flexibility.
The functional degree measured by the Bath Ankylosing
Spondylitis Functional Index (BASFI) was slightly higher in
TABLE 4. Parameters defining the disease activity of patients, by specific diagnosis
AS (n¼46) Ps-SpA (n¼51) uSpA (n¼43) P Total (n¼140)
Nocturnal back pain, VAS 0–10cm 3.8 3.0 3.1 3.3 2.9 2.3 0.31 3.2 2.9
Patient global assessment, VAS 0–10cm 4.3 2.6 4.8 2.7 4.2 2.8 0.49 4.4 2.7
Physician global assessment, VAS 0–10cm 3.2 2.3 3.4 2.4 3.3 2.1 0.92 3.3 2.2
ESR, mm/h 16.2 14.2 19.6 18.4 17.4 15.1 0.59 17.8 16
CRP, mg/l normal <5mg/l 6.1 11.1 12.1 19.2 8.0 11.1 0.13 8.8 14
BASDAI 3.8 2.4 4.6 2.3 3.9 2.6 0.32 4.1 2.4
Physical component SF-12 34.2 15.2 36.4 14.4 32.1 15.9 0.39 34.4 15
Mental component SF-12 43.4 17.7 45.1 16.3 42.0 19.4 0.70 43.6 18
Results are expressed as a mean  S.D. Significance was obtained by analysis of variance.
TABLE 3. Characteristics of patients on inclusion, by specific diagnosis
AS (n¼46) Ps-SpA (n¼51) uSpA (n¼43) P Total (n¼140)
Peripheral arthritis, n (%) 9 (20) 26 (51)
  9 (21)
   <0.001 44 (31)
Enthesitis, n (%) 11 (24) 7 (14) 11 (26) 0.49 29 (21)
Uveitis, n (%) 4 (9) 1 (2) 3 (7) 0.33 8 (6)
Clinic form (axial-mixed), n (%) 44 (96) 15 (29)
  31 (72)
 ,   <0.001 90 (64)
BASFI 2.8 2.6 2.8 2.5 2.4 2.3 0.74 2.7 2.4
Chest expansion, cm 4.9 2.6 4.0 1.5 5.1 2.0 0.06 4.7 2.2
Schober modified, cm 4.2 2.6 4.6 1.8 5.8 3.3
  0.016 4.9 2.7
Occiput-to-wall distance, cm 1.7 3.5 1.0 2.4 0.6 1.8 0.16 1.1 2.7
Finger-to-floor distance, cm 13.6 12 12.8 12.5 8.2 9.0
  0.06 11.6 11.4
Cervical rotation 208–708, n (%) 10 (22) 9 (18) 3 (7) 0.13 22 (16)
Results are expressed as the mean  S.D., unless otherwise specified. Significance obtained by the chi-square test for qualitative variables and analysis of variance for quantitative variables (Games–
Howell as post hoc test).
 Significant differences (P<0.05) vs AS.
  Significant differences (P<0.05) vs Ps-SpA.
406 Marena Rojas-Vargas et al.patients with AS, but did not reveal statistically significant dif-
ferences regarding uSpA (P¼0.51). The degree of bone damage
according to the BASRI for the spine (BASRI-s) and in total
(BASRI-t) was significantly higher in patients with AS (P<0.001,
in both the cases), also when analysed by each component.
Discussion
Different registries developed over the last few years have proven
useful for describing the epidemiological aspects, clinical patterns,
response to therapy, degree of impairment in quality of life and
socioeconomic impact associated with inflammatory rheumatic
diseases. Similarly, a dynamic registry such as REGISPONSER is
composed of a cohort with a significantly large enough number of
patients to enable us to determine the progress of these diseases
from onset. REGISPONSER-Early and REGISPONSER were
created to provide more specific information on the different sub-
cohorts of patients with SpA.
A surprising result is the average age at onset of symptoms in
all early cohorts and by diagnoses, which is almost 15 yrs higher
than the mean for REGISPONSER-Late sub-cohort (41.2 13.7
vs 26.7 12.5, respectively). A breakdown by diagnoses reveals
that Ps-SpA starts later than other SpA, with almost 12 yrs’
difference (similar to REGISPONSER-Late cohort, Ps-SpA
36.2 13.4, AS 25.1 9.0, uSpA 26.4 10.2). Although we may
consider that patients could present with vague symptoms, unclear
or poorly thought spondylitis many years before, here with this
early assessment of the beginning of the disease and diagnosis we
could assume that we are avoiding or minimizing the memory bias
and that patients could remember their first symptoms better.
Taking a look at other AS cohorts like GESPIC from Germany
and OASIS from the Netherlands, we can see that the mean age at
disease onset is higher the sooner it is assessed; however, disease
onset is not clearly defined and it is often not specified in
descriptive published data and we can only count with disease
duration data (not specifying if it is since symptom onset or
diagnosis), and recent efforts to redefine this last concept [8, 9] will
help us to know if this appreciation is valid. This fact, coupled
with the higher rate of SI damage over such a short period (54%
of the patients with AS show Grade II sacroiliitis, 37% Grade
III and 7% Grade IV) could indicate that these patients pre-
sented a short pre-radiographic pauci-symptomatic stage during
which their disease was damaging the joints and bone. This
contrasts with lengthy pre-radiographic phase of symptoms
reported by Mau et al. [10] that radiological sacroiliitis became
evident after at least 9 6 yrs and radiological signs of spinal
involvement after 11 6 yrs mean disease duration. This confirms
the difficulty to identify the beginning and maybe it is not yet
possible to determine the evolution time of these diseases when it
is diagnosed.
TABLE 5. Radiographic scores, by specific diagnosis
AS
(n¼46)
Ps-SpA
(n¼51)
uSpA
(n¼43)
P
Sacroiliitis grades II–IV, n (%) 46 (100) 9 (18)
  7 (17)
  <0.001
Lumbar spine 1 (0, 3) 0 (0, 2)
  0 (0, 1)
  <0.001
Cervical spine 1 (0, 3) 0 (0, 1)
  0 (0, 0)
 ,   0.001
SI joints 2 (2, 4) 0 (0, 3)
  1 (0, 3)
 ,   <0.001
BASRI-s 3 (0, 10) 0 (0, 4)
  1 (0, 3)
  <0.001
Hips 0 (0, 3) 0 (0, 2) 0 (0, 0)
  0.024
BASRI-t 3 (0, 10) 0 (0, 6)
  1 (0, 3)
  <0.001
Results are expressed as the median (minimum, maximum), unless otherwise specified.
Significance obtained by the chi-square test for qualitative variables and Kruskal–Wallis test for
ordinal variables (Mann–Whitney as post hoc test).
 Significant differences (P<0.05) vs AS.
  Significant differences (P<0.05) vs Ps-SpA.
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FIG. 1. Radiographic scores.
First signs and symptoms of SpA 407In our series, we saw that 31% of the patients met the modified
New York criteria for AS [11] during the 2 yrs after the first sign
or symptom attributable to the disease. Van der Heijde and
co-workers [12] showed that 20% of their series of 68 patients with
inflammatory spinal pain with a duration of 42 yrs [Early
Spondyloarthritis Clinic Cohort (ESPAC)] met the modified New
York criteria. Although cohorts are not comparable, this tells us
that a significant percentage of patients with SpA can be diag-
nosed almost at the beginning of this condition with the help of
registry data and diagnostic criteria [13, 14].
Another possible explanation is that SpA that starts later has a
more rapid and aggressive course, although this contrasts with
previous data showing that late-onset SpA has a less aggressive or
similar course [15, 16]. However, we must remember that errors in
data entry can occur when working with a registry (e.g. with the
onset date) and that this can affect results.
Diagnosis delay in this cohort was <1yr both globally and in
groups, much less than the 8–11 yrs reported by Feldtkeller et al.
[17] in a cohort of patients with AS. In Spain, diagnosis delay has
been observed to be 6.5 ( 8.4) yrs [3]. This fact highlights the
importance of early diagnosis and treatment of these diseases and
the effects of a delay in implementing the new treatments (physical
deterioration, lower quality of life, and increased social and health
care spending), as demonstrated by studies published since as
early as 2004 [18, 19]. Early treatment with new biological ther-
apies has been shown to give better results than applying them in
the advanced stages [20]. Therefore, diagnostic algorithms are now
being developed for patients with inflammatory spinal pain to
diagnose SpA during its earliest stages [21, 22]. MRI has been
proposed as a diagnostic imaging tool [20] to provide early data
on inflammation involving bone; however, this test has not yet
been included as a diagnostic criterion, despite its widespread use
in clinical practice.
Regarding the onset symptoms in this cohort, we found that
back pain was the most frequent symptom in the group as a
whole. In terms of diagnostic group, arthritis of the lower limbs
was more prevalent in the Ps-SpA group and the second most
frequent (after back pain) among uSpA patients. Arthritis of
the upper limbs was more prevalent at onset in Ps-SpA patients
than in the remaining SpA patients. Onset with enthesitis was
more common in uSpA patients. Dactylitis, although very rare as
the first manifestation, is more frequent in Ps-SpA and uSpA
patients, and we did not observe that the first manifestation of AS
was dactylitis. We found some differences in our sub-cohort
(REGISPONSER-Early) with respect to REGISPONSER-Late:
the most relevant differences between these cohorts were related to
upper limb peripheral arthritis (AS of REGISPONSER-Late
patients was 3% vs 15% in REGISPONSER-Early) and enthesitis
(uSpA of REGISPONSER-Late patients was 15% vs 28% in
REGISPONSER-Early). The data suggest that patients with early
diagnosis refer or may remember other signs/symptoms that those
with longer disease do not refer/remember.
With regard to clinical expression in this cohort, we found
an increased rate of peripheral joint involvement in Ps-SpA
patients, and an increased rate of enthesitis in AS and uSpA
patients. Although metrological measures showed a flexibility
change, all groups are within the normal range and the results
of the Schober’s test do not appear to be altered during the
first 2 yrs.
Radiological scores show that AS is the most affected SpA
globally and uSpA affects SI joint more than Ps-SpA, though this
last affects cervical spine more than uSpA. When the AS and
uSpA groups are compared, the former presented more bone
damage according to the BASRI and less flexibility according to
the various metrological data. In our cohort, we observed a
greater proportion of uSpA (28.6%) over the total of patients
included in the registry during the first phase [3]. However, as we
found no published data about cohorts with the same charac-
teristics, we cannot make comparisons. This finding is logical,
given that, by definition, uSpA corresponds to a group of diseases
that meet the criteria for SpA, but not the diagnostic criteria for
any defined entity. These patients may develop subsequent clinical
or radiological events enabling them to be differentiated, but they
can also remain in an undifferentiated state for many years.
At present, several cohorts are being formed, such as that of
Heuft-Dorenbosch et al. [12], with patients suffering from inflam-
matory spinal pain ESPAC cohort [11] and cohorts of patients
with early AS, such as the German cohort GESPIC [23].
Our study highlights the need to define the initial stages of SpA,
and to carry out a close follow-up of these cohorts to expand our
knowledge of the course and prognosis of this condition, and to
determine the response to treatment.
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